Atlas Trials

Combination of Intranasal Scopolamine and Sensory Augmentation to Mitigate G-transition Induced Motion Sickness and Enhance Sensorimotor Performance

Clinical trial NCT05886660 · UNKNOWN

Trial details

NCT number
NCT05886660
Sponsor
Repurposed Therapeutics, Inc.
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Motion Sickness, SpaceMotion SicknessSea Sickness
Start date
2022-01-21
Primary completion
2024-09-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.